Skip to main content
Smart Investors Daily
Bone Biologics Corporation logo

NASDAQ · BBLGW

Bone Biologics Corporation

Healthcare · Medical - Devices

$7.70

Up+$1.09 (+16.60%)

Updated Oct 11, 2026, 6:48 PM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
38.96M
P/E ratio
-0.86
Dividend yield
0.00%
52-week range
$3.50 – $21.00
Volume
13.39K
Avg. volume
71

Price performance · BBLGW

BBLGW price history

1M range · 11 trading sessions · Daily adjusted prices

Prices through Oct 9, 2026

BBLGW closed at $7.70 after 11 trading sessions, up 37.50% for the selected period.

Last close
$7.70
Period change
+37.50%
Period low
$3.80
Period high
$7.70
Daily close
View OHLC price history
BBLGW OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 9, 2026$5.39$12.00$5.39$7.7013.39K
Oct 6, 2026$6.535$6.535$6.535$6.535961
Oct 5, 2026$5.99$7.70$4.40$7.705.59K
Oct 2, 2026$5.99$7.99$5.53$5.535.5K
Oct 1, 2026$4.30$4.30$4.30$4.30478
Sep 30, 2026$4.28$4.28$3.80$3.801.21K
Sep 18, 2026$4.05$4.10$3.92$4.06635
Sep 17, 2026$5.70$5.70$4.22$4.301.04K
Sep 16, 2026$5.88$6.00$5.00$5.002.22K
Sep 15, 2026$7.30$7.48$6.10$6.103.01K
Sep 14, 2026$4.00$8.07$3.88$5.603.14K

Latest BBLGW news

The latest Smart Investors Daily articles mentioning BBLGW.

BBLGW research

Overview

Company profile and research snapshot.

Company profile

Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has applications in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 8, 2026

Bone Biologics Expands Trial Sites

Addition of three sites strengthens expectation to complete enrollment by year-end 2026BURLINGTON, MA, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for spine fusion markets, today announced that six hospital sites in Australia are now under agreement to participate in its first-in-human pilot clinical trial of NB1, the Company’s rhNELL-1-based bone graft product for spinal fusion. Th

defenseworld.net · Dec 12, 2025

Bone Biologics (NASDAQ:BBLGW) Trading Up 29.2% – Here’s Why

Bone Biologics Co. (NASDAQ: BBLGW - Get Free Report)'s stock price was up 29.2% during mid-day trading on Thursday. The stock traded as high as $21.75 and last traded at $21.70. Approximately 900 shares traded hands during trading, a decline of 39% from the average daily volume of 1,483 shares. The stock had previously closed

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.